Nightstar Therapeutics (NASDAQ:NITE) had its price target hoisted by analysts at Leerink Swann from $30.00 to $35.00 in a research report issued on Monday, The Fly reports. The brokerage currently has a “positive” rating on the stock. Leerink Swann’s price target would suggest a potential upside of 71.23% from the company’s previous close.

A number of other equities analysts have also recently weighed in on NITE. UBS Group cut Nightstar Therapeutics from an “outperform” rating to a “market perform” rating in a report on Wednesday, June 27th. Chardan Capital reissued a “buy” rating and issued a $40.00 price target on shares of Nightstar Therapeutics in a report on Wednesday, June 6th. Zacks Investment Research cut Nightstar Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, June 6th. Mizuho reissued a “buy” rating and issued a $20.00 price target on shares of Nightstar Therapeutics in a report on Tuesday, August 14th. Finally, Janney Montgomery Scott began coverage on Nightstar Therapeutics in a report on Wednesday, August 22nd. They issued a “buy” rating and a $34.00 price target for the company. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $32.86.

NASDAQ NITE opened at $20.44 on Monday. Nightstar Therapeutics has a fifty-two week low of $10.01 and a fifty-two week high of $29.55. The firm has a market capitalization of $716.55 million and a PE ratio of -12.54.

Nightstar Therapeutics (NASDAQ:NITE) last released its quarterly earnings results on Monday, August 13th. The company reported ($0.29) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.41) by $0.12. equities research analysts anticipate that Nightstar Therapeutics will post -1.62 EPS for the current year.

A number of institutional investors have recently added to or reduced their stakes in NITE. Bank of America Corp DE acquired a new position in Nightstar Therapeutics in the second quarter valued at $132,000. Stanley Laman Group Ltd. acquired a new position in Nightstar Therapeutics in the second quarter valued at $195,000. Millennium Management LLC acquired a new position in Nightstar Therapeutics in the first quarter valued at $507,000. Woodford Investment Management Ltd acquired a new position in Nightstar Therapeutics in the second quarter valued at $5,024,000. Finally, Partner Fund Management L.P. increased its stake in Nightstar Therapeutics by 0.7% in the second quarter. Partner Fund Management L.P. now owns 1,016,980 shares of the company’s stock valued at $16,272,000 after purchasing an additional 7,007 shares during the last quarter. Hedge funds and other institutional investors own 28.62% of the company’s stock.

About Nightstar Therapeutics

Nightstar Therapeutics PLC is a clinical-stage gene therapy company, which engages in the development and commercialization of novel one-time treatments for patients suffering from rare inherited retinal diseases. Its pipeline includes NSR-REP1, for the treatment of choroideremia; NSR-RPGR, for the treatment of X-linked retinitis pigmentosa; and NSR-BEST1, for the treatment of vitelliform macular dystrophy.

See Also: What is the NASDAQ?

The Fly

Analyst Recommendations for Nightstar Therapeutics (NASDAQ:NITE)

Receive News & Ratings for Nightstar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nightstar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.